Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO‐029 Antibody for Muscular Dystrophy

4 Oct 2016

Abstract excerpt

Suppression of the myostatin (GDF‐8) pathway has emerged as an important therapeutic paradigm for muscle‐wasting disorders. In this study, we conducted a translational pharmacokinetic/pharmacodynamic (PK/PD) analysis of MYO‐029, an anti‐myostatin monoclonal antibody, using PK data in mice, rats, monkeys, humans, mouse tissue distribution data with 125I‐labeled MYO‐029, muscle weight increase in SCID mice, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiomyopathy and Myosin Studies
Share to Genetic Neurodegenerative Diseases
Share to Muscle Physiology and Disorders

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 27700008
DOI: 10.1111/cts.12420

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Translational Pharmacokinetic/Pharmacodynamic Analysis of MYO‐029 Antibody for Muscular DystrophyPMID 27700008Read ↗

Novel Myostatin-Specific Antibody Enhances Muscle Strength in Muscle Disease ModelsSemantic proximity Read ↗

Therapeutic applications and challenges in myostatin inhibition for enhanced skeletal muscle mass and functionsSemantic proximity Read ↗

A VLP-based immunogen that elicits selective anti-Myostatin antibodies, enhances muscle mass and strength, and reduces adipositySemantic proximity Read ↗

Myostatin Inhibitors: Panacea or Predicament for Musculoskeletal Disorders?Semantic proximity Read ↗

[Myostatin blockade therapy for muscular atrophy].Semantic proximity Read ↗

[Pharmacological and clinical profiles of panitumumab injection (Vectibix®)].Semantic proximity Read ↗

Myostatin as a therapeutic target for musculoskeletal disease.Semantic proximity Read ↗

Interference with Myostatin/ActRIIB Signaling as a Therapeutic Strategy for Duchenne Muscular DystrophySemantic proximity Read ↗

Potent and durable gene modulation in heart and muscle with chemically defined siRNAsSemantic proximity Read ↗

The elusive promise of myostatin inhibition for muscular dystrophy.Semantic proximity Read ↗

Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015Semantic proximity Read ↗

Quantitative Prediction of Human Pharmacokinetics for Fc-Engineered Therapeutic Monoclonal Antibodies With Increased FcRn Binding Mutations After Subcutaneous Injection.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.